Canadian Xarelto Lawsuits Continue to Emerge

Posted on July 25, 2016

Lawsuits over excessive bleeding related to Xarelto continue to mount here in the United States, but they are also growing in our neighbor to the north. In two cases in particular, Canadian attorneys have listed pharmaceutical giants Johnson & Johnson and Bayer, the makers of Xarelto (rivaroxaban), as defendants in civil suits. In one case, a Calgary woman nearly suffered a heart attack after an episode of severe internal bleeding while on Xarelto. In another, an Ontario woman bled to death while in the shower. Those are just two of more than 1,100 Xarelto lawsuits filed in Canada in recent years.

Xarelto was developed to compete with the long used blood thinner warfarin (Coumadin), which required strict diet control and frequent blood monitoring. Xarelto was seen as a breakthrough medication because it didn’t require diet restrictions and blood monitoring. While both warfarin and Xarelto can cause excessive bleeding, the difference is that warfarin has an antidote and Xarelto currently does not. Plaintiffs are alleging that Xarelto was rushed to the marketplace by its manufacturers before a viable, life-saving antidote was developed, thus putting millions of lives at risk.

If you’ve lost a loved one who was being treated with Xarelto, you and your family may be able to pursue compensation for your losses in a wrongful death claim. If you yourself have suffered excessive bleeding after being treated with Xarelto, you may be able to pursue compensation for lost wages, medical bills, pain and suffering, permanent injury, and other damages. To get the settlement you deserve, you’ll need the reputation of a trusted and dedicated personal injury attorney.

The legal team at the law offices of Farah & Farah can guide you through the entire legal process. We are currently investigating Xarelto related injury claims nationwide. Call our offices at (800) 533-3555 for a free consultation.

  • This field is for validation purposes and should be left unchanged.